title: Summary of recombinant human serum albumin development.
abstract: The methylotrophic yeast Pichia pastoris is well known as a host strain for the production of a variety of heterologous proteins. We have used P. pastoris for the production of recombinant human serum albumin (rHSA), for which we have developed efficient and specialized downstream processes. Results from structural analysis suggest that purified rHSA possesses an identical conformation to plasma derived human albumin (pdHA) and no difference from pdHA has been observed in neo-antigenicity. Host-cell-derived impurities (i.e. Pichia yeast component, DNA and mannan) have been evaluated in the purification process as well as in the drug substance and relevant specifications established. The efficacy and safety of rHSA have been tested in clinical studies and no difference from pdHA has been found in comparative study. Such studies have confirmed rHSA to have high efficacy with little or no adverse reaction.
authors.affiliation: Protein Research Laboratory, Mitsubishi Pharma Corporation, 2-25-1, Shodai-Ohtani, Hirakata, Osaka 573-1153, Japan. kobayashi.kaoru@m-pharma.co.jp
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kobayashi
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D010843:Pichia / Q000378:metabolism; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000302:isolation & purification / Q000592:standards*; D012709:Serum Albumin / Q000096:biosynthesis* / Q000302:isolation & purification / Q000592:standards*
chemical_list: D011994:Recombinant Proteins; D012709:Serum Albumin